印度高血压孕妇引产:Foley导尿管与口服米索前列醇的成本-结局分析及临床试验
该研究基于印度纳格浦尔两家公立医院602名因子痫前期或高血压需终止妊娠的孕妇,开展多中心平行开放标签随机试验的成本-结局分析。口服米索前列醇25微克组较Foley导尿管组医疗支出平均减少20.6美元,24小时内阴道分娩率提高10%,缩宫素使用时间减少135.3分钟,剖宫产率降低9.1%。作者认为口服米索前列醇可改善24小时内阴道分娩率并可能降低成本,但需在其他低资源地区进一步研究以确定相对成本效果。
要点
- 口服米索前列醇组较Foley导尿管组医疗支出平均减少20.6美元,24小时内阴道分娩率提高10%。
- 口服米索前列醇组缩宫素使用时间减少135.3分钟,剖宫产率降低9.1%。
- 概率敏感性分析显示口服米索前列醇在63%的模拟中节约成本,在99.4%的模拟中24小时内阴道分娩率更优。
核心结论
- 与Foley导尿管引产相比,口服米索前列醇可提高高血压高危孕妇24小时内阴道分娩率,并可能降低费用。
- 作者认为需在其他低资源地区开展进一步研究以确定两种方法的相对成本效果。
研究设计与样本
- 基于既往报告的多中心、平行、开放标签随机试验(INFORM临床试验)的成本-结局分析。
- 共纳入602名年龄≥18岁、因子痫前期或高血压需终止妊娠且胎儿存活的孕妇,来自印度纳格浦尔两家公立医院。
- 孕妇随机接受经宫颈Foley导尿管或口服米索前列醇25微克引产。
- 采用供方微观成本法计算医疗支出。
主要发现
- 口服米索前列醇组较Foley导尿管组医疗支出平均减少20.6美元,95%CI为-123.59至-72.49美元。
- 口服米索前列醇组24小时内阴道分娩率平均提高10%,95%CI为-2%至17.9%,P=0.016。
- 口服米索前列醇组缩宫素使用时间减少135.3分钟,95%CI为84.4至186.2分钟,P<0.01。
- 口服米索前列醇组剖宫产率降低9.1%,95%CI为1.1%至17%,P=0.025。
- 概率敏感性分析中,口服米索前列醇在5000次bootstrap重复的63%中节约成本,在98.7%、90.7%和99.4%的模拟中分别实现更高的阴道分娩率、24小时内分娩率和24小时内阴道分娩率。
局限性
- 作者认为需在其他低资源地区开展进一步研究以确定两种方法的相对成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effectiveness and economic impact of two methods for induction of labour in hypertensive women, in low-resource settings. DESIGN: Cost-consequence analysis of a previously reported multicentre, parallel, open-label randomised trial. SETTING & POPULATION: A total of 602 women with a live fetus, aged ≥18 years requiring delivery for pre-eclampsia or hypertension, in two public hospitals in Nagpur, India. METHODS: We performed a formal economic evaluation alongside the INFORM clinical trial. Women were randomised to receive transcervical Foley catheterisation or oral misoprostol 25 mcg. Healthcare expenditure was calculated using a provider-side microcosting approach. MAIN OUTCOME MEASURES: Rates of vaginal this delivery within 24 hours of induction, healthcare expenditure per completed treatment episode. RESULTS: Induction with oral misoprostol resulted in a (mean difference) $20.6USD reduction in healthcare expenditure [95% CI (-) $123.59 (-) $72.49], and improved achievement of vaginal delivery within 24 hours of induction, mean difference 10% [95% CI (-2 to 17.9%), P = 0.016]. Oxytocin administration time was reduced by 135.3 minutes [95% CI (84.4-186.2 minutes), P < 0.01] and caesarean sections by 9.1% [95% CI (1.1-17%), P = 0.025] for those receiving oral misoprostol. Following probabilistic sensitivity analysis, oral misoprostol was cost-saving in 63% of 5,000 bootstrap replications and achieved superior rates of vaginal delivery, delivery within 24 hours of induction and vaginal delivery within 24 hours of induction in 98.7%, 90.7%, and 99.4% of bootstrap simulations. Based on univariate threshold analysis, the unit price of oral misoprostol 25 mcg could feasibly increase 31-fold from $0.24 to $7.50 per 25 mcg tablet and remain cost-saving. CONCLUSION: Compared to Foley catheterisation for the induction of high-risk hypertensive women, oral misoprostol improves rates of vaginal delivery within 24 hours of induction and may also reduce costs. Additional research performed in other low-resource settings is required to determine their relative cost-effectiveness. TWEETABLE ABSTRACT: Oral misoprostol less costly and more effective than Foley catheter for labour induction in hypertension.
引用
- Leigh S, Granby P, Haycox A, et al. Foley catheter vs. oral misoprostol to induce labour among hypertensive women in India: a cost-consequence analysis alongside a clinical trial. BJOG. 2018. PMID: 29782065. doi:10.1111/1471-0528.15285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。